Search research articles
Contact Us
Filters
Showing results (81-90 of 92) with videos related to
Page
of 10
Sort By:
International Journal of Cardiology
|
February 11, 2014
Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study
Anne Funke-Kaiser, Kristy Mann, David Colquhoun, et al.
Cardiology and Therapy
|
October 25, 2024
Asia-Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study
Hung-Fat Tse, Hung-Yu Chang, David Colquhoun, et al.
Circulation
|
March 13, 2002
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
R John Simes, Ian C Marschner, David Hunt, et al.
Journal of the American College of Cardiology
|
October 22, 2013
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease)
Harvey D White, Andrew Tonkin, John Simes, et al.
Journal of the American College of Cardiology
|
May 6, 2014
Reply: the latest generation of troponin immunoassays: the "cholesterol" of the third millennium?
Harvey D White, Andrew Tonkin, John Simes, et al.
Heart, Lung & Circulation
|
July 29, 2023
A Clinical Guide for Assessment and Prescription of Exercise and Physical Activity in Cardiac Rehabilitation. A CSANZ Position Statement
Christian Verdicchio, Nicole Freene, Matthew Hollings, et al.
Journal of the American College of Cardiology
|
April 4, 2014
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
Erik Stroes, David Colquhoun, David Sullivan, et al.
Heart, Lung & Circulation
|
June 1, 2020
Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement From the Cardiac Society of Australia and New Zealand (CSANZ)
Stephen J Nicholls, Mark Nelson, Carolyn Astley, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
September 5, 2018
Detailed Polysomnography in Australian Vietnam Veterans With and Without Posttraumatic Stress Disorder
Timothy Baird, Rebecca Theal, Sarah Gleeson, et al.
Heart, Lung & Circulation
|
January 8, 2026
Corrigendum to: "Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations" [Heart Lung Circ. 32(3) (2023) 287-296.]
Natalie C Ward, Gerald F Watts, Warrick Bishop, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 92) with videos related to
Sort By:
Page
of 10
International Journal of Cardiology
|
February 11, 2014
Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study
Anne Funke-Kaiser, Kristy Mann, David Colquhoun, et al.
Cardiology and Therapy
|
October 25, 2024
Asia-Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study
Hung-Fat Tse, Hung-Yu Chang, David Colquhoun, et al.
Circulation
|
March 13, 2002
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
R John Simes, Ian C Marschner, David Hunt, et al.
Journal of the American College of Cardiology
|
October 22, 2013
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease)
Harvey D White, Andrew Tonkin, John Simes, et al.
Journal of the American College of Cardiology
|
May 6, 2014
Reply: the latest generation of troponin immunoassays: the "cholesterol" of the third millennium?
Harvey D White, Andrew Tonkin, John Simes, et al.
Heart, Lung & Circulation
|
July 29, 2023
A Clinical Guide for Assessment and Prescription of Exercise and Physical Activity in Cardiac Rehabilitation. A CSANZ Position Statement
Christian Verdicchio, Nicole Freene, Matthew Hollings, et al.
Journal of the American College of Cardiology
|
April 4, 2014
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
Erik Stroes, David Colquhoun, David Sullivan, et al.
Heart, Lung & Circulation
|
June 1, 2020
Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement From the Cardiac Society of Australia and New Zealand (CSANZ)
Stephen J Nicholls, Mark Nelson, Carolyn Astley, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
September 5, 2018
Detailed Polysomnography in Australian Vietnam Veterans With and Without Posttraumatic Stress Disorder
Timothy Baird, Rebecca Theal, Sarah Gleeson, et al.
Heart, Lung & Circulation
|
January 8, 2026
Corrigendum to: "Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations" [Heart Lung Circ. 32(3) (2023) 287-296.]
Natalie C Ward, Gerald F Watts, Warrick Bishop, et al.
Page
of 10